CN101821283A - Slit,nephrin,肝配蛋白或脑信号蛋白用于治疗软骨疾病的用途 - Google Patents

Slit,nephrin,肝配蛋白或脑信号蛋白用于治疗软骨疾病的用途 Download PDF

Info

Publication number
CN101821283A
CN101821283A CN200880111279A CN200880111279A CN101821283A CN 101821283 A CN101821283 A CN 101821283A CN 200880111279 A CN200880111279 A CN 200880111279A CN 200880111279 A CN200880111279 A CN 200880111279A CN 101821283 A CN101821283 A CN 101821283A
Authority
CN
China
Prior art keywords
leu
ser
asn
arg
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880111279A
Other languages
English (en)
Chinese (zh)
Inventor
A·鲍瑟尔霍夫
T·舒伯特
E·哈斯特尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fumaikang Co Ltd
Original Assignee
Scil Technology GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07018131A external-priority patent/EP2036921A1/en
Application filed by Scil Technology GmbH filed Critical Scil Technology GmbH
Publication of CN101821283A publication Critical patent/CN101821283A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN200880111279A 2007-09-14 2008-09-12 Slit,nephrin,肝配蛋白或脑信号蛋白用于治疗软骨疾病的用途 Pending CN101821283A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07018131A EP2036921A1 (en) 2007-09-14 2007-09-14 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP07018131.8 2007-09-14
EP08006810 2008-04-03
EP08006810.9 2008-04-03
PCT/EP2008/007579 WO2009033715A2 (en) 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases

Publications (1)

Publication Number Publication Date
CN101821283A true CN101821283A (zh) 2010-09-01

Family

ID=40452588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880111279A Pending CN101821283A (zh) 2007-09-14 2008-09-12 Slit,nephrin,肝配蛋白或脑信号蛋白用于治疗软骨疾病的用途

Country Status (13)

Country Link
US (1) US20110002972A1 (enExample)
EP (1) EP2212344B1 (enExample)
JP (1) JP2010539123A (enExample)
KR (1) KR20100075493A (enExample)
CN (1) CN101821283A (enExample)
AU (1) AU2008297889A1 (enExample)
BR (1) BRPI0816784A8 (enExample)
CA (1) CA2699411A1 (enExample)
MX (1) MX2010002716A (enExample)
NZ (1) NZ583851A (enExample)
RU (1) RU2496790C2 (enExample)
WO (1) WO2009033715A2 (enExample)
ZA (1) ZA201001644B (enExample)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703021A (zh) * 2010-12-23 2014-04-02 赛诺菲 用于治疗肝癌的Robo1-Fc融合蛋白
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104582727A (zh) * 2012-06-15 2015-04-29 财团法人峩山社会福祉财团 利用Slit-Robo系统用于预防或治疗骨折或骨质疏松症的组合物
CN110684805A (zh) * 2019-11-19 2020-01-14 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
CN110694051A (zh) * 2019-11-19 2020-01-17 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
CN110711244A (zh) * 2019-11-19 2020-01-21 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110721308A (zh) * 2019-11-19 2020-01-24 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110772632A (zh) * 2019-11-19 2020-02-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110841057A (zh) * 2019-11-19 2020-02-28 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN113557034A (zh) * 2019-02-27 2021-10-26 株式会社大熊制药 包含与白蛋白结合的Slit3蛋白的LRRD2的用于预防或治疗骨相关疾病的组合物
CN114555814A (zh) * 2019-09-13 2022-05-27 罗特格斯新泽西州立大学 Aav相容的层粘连蛋白-连接子聚合蛋白

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
ES3013463T3 (en) * 2011-07-04 2025-04-14 Mesoblast Inc Treating or preventing rheumatic disease
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
JPWO2015072527A1 (ja) * 2013-11-13 2017-03-16 国立大学法人大阪大学 ネトリン１含有破骨細胞形成抑制剤
EP3116521B1 (en) * 2014-03-14 2024-07-31 The Research Foundation for The State University of New York Neurogenic regulation of bone growth and bone degradation
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US20200397860A1 (en) * 2018-02-14 2020-12-24 Cornell University Slit and bone growth modulation
JPWO2023008337A1 (enExample) * 2021-07-26 2023-02-02

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
JPH1116490A (ja) * 1997-06-26 1999-01-22 Kyocera Corp プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1203999A (en) * 1997-10-31 1999-05-24 Osiris Therapeutics, Inc. Human slit polypeptide and polynucleotides encoding same
JPH11164690A (ja) * 1997-12-05 1999-06-22 Asahi Chem Ind Co Ltd 脊椎動物スリット蛋白質
US6924355B2 (en) * 1998-09-01 2005-08-02 Genentech, Inc. PRO1343 polypeptides
AU3755100A (en) * 1999-03-17 2000-10-04 Washington University Vertebrate slit dna sequence, protein and uses thereof
AU2001278655A1 (en) * 2000-07-18 2002-01-30 Compugen Ltd. Novel nucleic acid and amino acid sequences
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
AU2001286446A1 (en) * 2000-08-10 2002-02-18 Pharmacia Corporation A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
US20060025335A1 (en) * 2004-01-30 2006-02-02 Kinane Thomas B Netrin compositions and methods of using the same
CN101600451A (zh) * 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703021A (zh) * 2010-12-23 2014-04-02 赛诺菲 用于治疗肝癌的Robo1-Fc融合蛋白
CN104582727A (zh) * 2012-06-15 2015-04-29 财团法人峩山社会福祉财团 利用Slit-Robo系统用于预防或治疗骨折或骨质疏松症的组合物
US9802994B2 (en) 2012-06-15 2017-10-31 The Asan Foundation Composition for preventing or treating fracture or osteoporosis using slit-robo system
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN113557034B (zh) * 2019-02-27 2024-10-01 株式会社大熊制药 包含与白蛋白结合的Slit3蛋白的LRRD2的用于预防或治疗骨相关疾病的组合物
CN113557034A (zh) * 2019-02-27 2021-10-26 株式会社大熊制药 包含与白蛋白结合的Slit3蛋白的LRRD2的用于预防或治疗骨相关疾病的组合物
CN114555814A (zh) * 2019-09-13 2022-05-27 罗特格斯新泽西州立大学 Aav相容的层粘连蛋白-连接子聚合蛋白
CN110721308A (zh) * 2019-11-19 2020-01-24 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110772632A (zh) * 2019-11-19 2020-02-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110841057A (zh) * 2019-11-19 2020-02-28 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN110711244A (zh) * 2019-11-19 2020-01-21 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110694051A (zh) * 2019-11-19 2020-01-17 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
CN110721308B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110694051B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
CN110711244B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110772632B (zh) * 2019-11-19 2023-08-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110684805A (zh) * 2019-11-19 2020-01-14 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用

Also Published As

Publication number Publication date
RU2010114713A (ru) 2011-10-20
BRPI0816784A8 (pt) 2016-01-19
US20110002972A1 (en) 2011-01-06
WO2009033715A3 (en) 2010-03-18
RU2496790C2 (ru) 2013-10-27
BRPI0816784A2 (pt) 2015-03-24
AU2008297889A1 (en) 2009-03-19
KR20100075493A (ko) 2010-07-02
CA2699411A1 (en) 2009-03-19
EP2212344A2 (en) 2010-08-04
ZA201001644B (en) 2011-03-30
EP2212344B1 (en) 2014-03-26
JP2010539123A (ja) 2010-12-16
NZ583851A (en) 2012-06-29
MX2010002716A (es) 2010-07-05
WO2009033715A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
EP2212344B1 (en) Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
JP5484059B2 (ja) 脊髄核インプラント
AU2785499A (en) Use of follistatin to modulate gdf-8 and bmp-11
Madry et al. Clinical potential and challenges of using genetically modified cells for articular cartilage repair
EP3250223A1 (en) Methods for the regeneration of articular cartilage in vivo
US20250345393A1 (en) Isoform nell-1 peptide
JP5856117B2 (ja) 細胞シグナル伝達タンパク質ｎｅｌｌ１を用いた、創傷治癒及び筋再生の促進方法
US8691944B2 (en) Fibronectin polypeptides and methods of use
EP2036921A1 (en) Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
US10130687B2 (en) Compositions and methods for the treatment of orthopedic disease or injury
US20120208753A1 (en) Composition and Method for the Treatment or Prevention of Spinal Disorders III
WO2010135915A1 (zh) 中期因子蛋白的用途及含该蛋白的医用装置
WO2008028888A2 (en) Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting
EP1192181B1 (en) Modulation of angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor for the treatment of tumor
WO2008077938A1 (en) Modulators of talin/integrin association and use thereof
WO2000076456A2 (en) Modulators of fibrosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: FUMAIKANG CO., LTD.

Free format text: FORMER OWNER: SCIL TECHNOLOGY GMBH

Effective date: 20120331

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20120331

Address after: German Pla Neg

Applicant after: Fumaikang Co., Ltd.

Address before: German Madingsilide

Applicant before: SCIL Technology GmbH

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100901